KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT02867007 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Cancer
Carcinoma

Interventions

DRUG: KHK2455
DRUG: Mogamulizumab

Sponsor

Kyowa Kirin, Inc.